網膜の健康市場 : 2030年までの予測

出版：Market Research Future（マーケットリサーチフューチャー）　出版年月：2022年12月

Retina Health Market Forecast till 2030
網膜の健康市場 : 2030年までの予測

レポート目次　　　　お問合せ・ご注文　　　　価格・納期について

Retina Health Market Forecast till 2030

Market Overview
During the forecast period, the retina health market is anticipated to grow at a CAGR of 7.01%. The term “retina” refers to the thin layer located at the back of the eye that transforms light entering the eye into electrical signals that the brain may process into images. The prevention of vision problems and even blindness depends on a healthy retina. The increasing frequency of retinal disorders worldwide and the increase in strategic initiatives are credited with driving the growth of the global market for retinal health. In addition, more public and private groups are taking action to raise awareness of retinal illnesses. However, it is projected that the dearth of knowledge about retinal illnesses may impede market expansion.
The global retina health market is expected to witness a substantial market expansion due to the increasing incidences of retinal illnesses like retinitis pigmentosa, diabetic retinopathy, Age-Related Macular Degeneration (AMD), and retinal detachment. Additionally, the market has grown because of the rising prevalence of myopia and cases of vision impairment, particularly during the COVID-19 epidemic. This is because more people are using screens and participating in virtual meetings while working from home, which has increased the prevalence of myopia and raised the chance of developing other progressive eye diseases including AMD. Additionally, growing consumer knowledge of retinal biologics fuels market expansion.
Market Segmentation
Based on the treatment and disease indication, the global market for retinal health has been segmented. The market is divided into categories for medications, therapy, and surgery based on the type of treatment. The global retina health market has been divided into age-related macular degeneration, diabetic retinopathy, inherited retinal illnesses, retinoblastoma, and others based on the indication of the disease.
Regional Analysis
Because of the high prevalence of retinal illnesses and the presence of significant market participants in the region, the North American retina health market is expanding. Due to reasons like the high prevalence of wet AMD, rising diabetes rates, and many elderly individuals, the European retina health market is expanding. Due to the rapidly developing healthcare infrastructure, rising per capita income, rising public awareness of eye health, and the presence of a sizable senior population, the Asia-Pacific (APAC) retina health market is anticipated to register a robust CAGR of 8.33% from 2022 to 2030.
The Middle East, Africa, and Latin America are the remainder of the world. Due to its weak economy, inadequate healthcare infrastructure, lack of qualified experts, and low level of public awareness, the remainder of the globe is predicted to have a slower CAGR than other regions.
Major Players
The key players operating in the global retina health market include Gensight Biologics (France), Novartis AG (Switzerland), Spark Therapeutics, Inc. (Us), Allergan Plc (Subsidiary of AbbVie Inc.) (Ireland), Hemera Biosciences LLC (US), Santen Pharmaceuticals Inc. (Japan), Regenxbio Inc. (US), Oxford Biomedica Plc (UK), Meiragtx Limited (US), Applied Genetic Technologies Corporation (AGTC) (US).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

目次

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING

3.2 SECONDARY RESEARCH

3.3 PRIMARY RESEARCH

3.4 BREAKDOWN OF PRIMARY RESPONDENTS

3.5 FORECASTING TECHNIQUES

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION

3.6.1 BOTTOM-UP APPROACH

3.6.2 TOP-DOWN APPROACH

3.7 DATA TRIANGULATION

3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW

4.2 DRIVERS

4.2.1 GROWING PREVALENCE OF RETINAL DISEASES ACROSS THE GLOBE

4.2.2 RISING NUMBER OF STRATEGIC INITIATIVES

4.3 RESTRAINTS

4.3.1 LACK OF AWARENESS REGARDING RETINAL DISEASES

4.4 OPPORTUNITY

4.4.1 INCREASING INITIATIVES BY PUBLIC AND PRIVATE ORGANIZATIONS TO DRIVE AWARENESS REGARDING RETINAL DISEASES

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS

5.1.1 R&D

5.1.2 MANUFACTURING

5.1.3 DISTRIBUTION & SALES

5.1.4 POST-SALES MONITORING

5.2 PORTER’S FIVE FORCES MODEL

5.2.1 THREAT OF NEW ENTRANTS

5.2.2 BARGAINING POWER OF SUPPLIERS

5.2.3 THREAT OF SUBSTITUTES

5.2.4 BARGAINING POWER OF BUYERS

5.2.5 INTENSITY OF RIVALRY

5.3 IMPACT OF COVID-19 ON THE RETINA HEALTH MARKET

5.3.1 IMPACT ON SUPPLY CHAIN

5.3.2 IMPACT ON PRODUCTION

5.3.3 IMPACT ON MARKET PLAYERS

5.3.4 IMPACT ON DEMAND

6 GLOBAL RETINA HEALTH MARKET, BY TREATMENT

6.1 OVERVIEW

6.2 DRUGS

6.3 THERAPY

6.3.1 GENE THERAPY

6.3.2 NUTRITION THERAPY

6.3.3 OTHERS

6.4 SURGERY

7 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION

7.1 OVERVIEW

7.2 AGE-RELATED MACULAR DEGENERATION

7.3 DIABETIC RETINOPATHY

7.4 INHERITED RETINAL DISEASES

7.5 RETINOBLASTOMA

7.6 OTHERS

8 GLOBAL RETINA HEALTH MARKET, BY REGION

8.1 OVERVIEW

8.2 NORTH AMERICA

8.2.1 US

8.2.2 CANADA

8.3 EUROPE

8.3.1 GERMANY

8.3.2 UK

8.3.3 FRANCE

8.3.4 ITALY

8.3.5 SPAIN

8.3.6 REST OF EUROPE

8.4 ASIA-PACIFIC

8.4.1 JAPAN

8.4.2 CHINA

8.4.3 INDIA

8.4.4 AUSTRALIA

8.4.5 SOUTH KOREA

8.4.6 REST OF ASIA-PACIFIC

8.5 REST OF THE WORLD

8.5.1 MIDDLE EAST

8.5.2 AFRICA

8.5.3 LATIN AMERICA

9 COMPETITIVE LANDSCAPE

9.1 OVERVIEW

9.2 COMPETITIVE BENCHMARKING

9.3 MAJOR GROWTH STRATEGY IN THE GLOBAL RETINA HEALTH MARKET

9.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL RETINA HEALTH MARKET

9.5 KEY DEVELOPMENT ANALYSIS

9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

9.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL

9.6.2 MERGER & ACQUISITIONS

9.6.3 EXPANSION

9.6.4 AGREEMENT/MARKETING STRATEGIES

9.7 FINANCIAL MATRIX

9.7.1 SALES (USD MILLION), 2021

9.7.2 RESEARCH & DEVELOPMENT EXPENDITURE (USD MILLION), 2021

10 COMPANY PROFILES

10.1 NOVARTIS AG

10.1.1 COMPANY OVERVIEW

10.1.2 FINANCIAL OVERVIEW

10.1.3 PRODUCTS/SERVICES OFFERED

10.1.4 KEY DEVELOPMENTS

10.1.5 SWOT ANALYSIS

10.1.6 KEY STRATEGIES

10.2 SPARK THERAPEUTICS, INC.

10.2.1 COMPANY OVERVIEW

10.2.2 FINANCIAL OVERVIEW

10.2.3 PRODUCTS/SERVICES OFFERED

10.2.4 KEY DEVELOPMENTS

10.2.5 KEY STRATEGIES

10.3 GENSIGHT BIOLOGICS

10.3.1 COMPANY OVERVIEW

10.3.2 FINANCIAL OVERVIEW

10.3.3 PRODUCTS/SERVICES OFFERED

10.3.4 KEY DEVELOPMENTS

10.3.5 KEY STRATEGIES

10.4 ALLERGAN PLC (SUBSIDIARY OF ABBVIE INC.)

10.4.1 COMPANY OVERVIEW

10.4.2 FINANCIAL OVERVIEW

10.4.3 PRODUCTS/SERVICES OFFERED

10.4.4 KEY DEVELOPMENTS

10.4.5 SWOT ANALYSIS

10.4.6 KEY STRATEGIES

10.5 OXFORD BIOMEDICA PLC

10.5.1 COMPANY OVERVIEW

10.5.2 FINANCIAL OVERVIEW

10.5.3 PRODUCTS/SERVICES OFFERED

10.5.4 KEY DEVELOPMENTS

10.5.5 KEY STRATEGIES

10.6 HEMERA BIOSCIENCES LLC

10.6.1 COMPANY OVERVIEW

10.6.2 FINANCIAL OVERVIEW

10.6.3 PRODUCTS/SERVICES OFFERED

10.6.4 KEY DEVELOPMENTS

10.6.5 SWOT ANALYSIS

10.6.6 KEY STRATEGIES

10.7 SANTEN PHARMACEUTICALS INC.

10.7.1 COMPANY OVERVIEW

10.7.2 FINANCIAL OVERVIEW

10.7.3 PRODUCTS OFFERED

10.7.4 KEY DEVELOPMENTS

10.7.5 SWOT ANALYSIS

10.7.6 KEY STRATEGIES

10.8 REGENXBIO INC.

10.8.1 COMPANY OVERVIEW

10.8.2 FINANCIAL OVERVIEW

10.8.3 PRODUCTS OFFERED

10.8.4 KEY DEVELOPMENTS

10.8.5 SWOT ANALYSIS

10.8.6 KEY STRATEGIES

10.9 MEIRAGTX LIMITED

10.9.1 COMPANY OVERVIEW

10.9.2 FINANCIAL OVERVIEW

10.9.3 PRODUCTS OFFERED

10.9.4 KEY DEVELOPMENTS

10.9.5 KEY STRATEGIES

10.10 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC)

10.10.1 COMPANY OVERVIEW

10.10.2 FINANCIAL OVERVIEW

10.10.3 PRODUCTS OFFERED

10.10.4 KEY DEVELOPMENTS

10.10.5 KEY STRATEGIES

11 APPENDIX

11.1 REFERENCES

11.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS

TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

TABLE 3 GLOBAL RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 4 COMMON RETINA DRUGS

TABLE 5 GLOBAL RETINA HEALTH MARKET, FOR DRUGS, BY REGION, 2018–2030 (USD MILLION)

TABLE 6 GLOBAL RETINA HEALTH MARKET, FOR THERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 7 GLOBAL RETINA HEALTH MARKET, FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 8 GLOBAL RETINA HEALTH MARKET, FOR GENE THERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 9 GLOBAL RETINA HEALTH MARKET, FOR NUTRITION THERAPY, BY REGION, 2018–2030 (USD MILLION)

TABLE 10 GLOBAL RETINA HEALTH MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 11 GLOBAL RETINA HEALTH MARKET, FOR SURGERY, BY REGION, 2018–2030 (USD MILLION)

TABLE 12 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 13 GLOBAL RETINA HEALTH MARKET, FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018–2030 (USD MILLION)

TABLE 14 GLOBAL RETINA HEALTH MARKET, FOR DIABETIC RETINOPATHY, BY REGION, 2018–2030 (USD MILLION)

TABLE 15 GLOBAL RETINA HEALTH MARKET, FOR INHERITED RETINAL DISEASES, BY REGION, 2018–2030 (USD MILLION)

TABLE 16 GLOBAL RETINA HEALTH MARKET, FOR RETINOBLASTOMA, BY REGION, 2018–2030 (USD MILLION)

TABLE 17 GLOBAL RETINA HEALTH MARKET, FOR OTHERS, BY REGION, 2018–2030 (USD MILLION)

TABLE 18 GLOBAL: RETINA HEALTH MARKET, BY REGION, 2018–2030 (USD MILLION)

TABLE 19 NORTH AMERICA: RETINA HEALTH MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 20 NORTH AMERICA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 21 NORTH AMERICA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 22 NORTH AMERICA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 23 US: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 24 US: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 25 US: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 26 CANADA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 27 CANADA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 28 CANADA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 29 EUROPE: RETINA HEALTH MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 30 EUROPE: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 31 EUROPE: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 32 EUROPE: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 33 GERMANY: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 34 GERMANY: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 35 GERMANY: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 36 UK: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 37 UK: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 38 UK: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 39 FRANCE: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 40 FRANCE: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 41 FRANCE: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 42 ITALY: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 43 ITALY: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 44 ITALY: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 45 SPAIN: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 46 SPAIN: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 47 SPAIN: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 48 REST OF EUROPE: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 49 REST OF EUROPE: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 50 REST OF EUROPE: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC: RETINA HEALTH MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 55 JAPAN: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 56 JAPAN: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 57 JAPAN: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 58 CHINA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 59 CHINA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 60 CHINA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 61 INDIA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 62 INDIA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 63 INDIA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 64 AUSTRALIA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 65 AUSTRALIA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 66 AUSTRALIA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 67 SOUTH KOREA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 68 SOUTH KOREA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 69 SOUTH KOREA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 70 REST OF ASIA-PACIFIC: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 71 REST OF ASIA-PACIFIC: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 72 REST OF ASIA-PACIFIC: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 73 REST OF THE WORLD: RETINA HEALTH MARKET, BY COUNTRY, 2018–2030 (USD MILLION)

TABLE 74 REST OF THE WORLD: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 75 REST OF THE WORLD: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 76 REST OF THE WORLD: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 77 MIDDLE EAST: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 78 MIDDLE EAST: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 79 MIDDLE EAST: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 80 AFRICA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 81 AFRICA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 82 AFRICA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 83 LATIN AMERICA: RETINA HEALTH MARKET, BY TREATMENT, 2018–2030 (USD MILLION)

TABLE 84 LATIN AMERICA: RETINA HEALTH MARKET FOR THERAPY, BY TYPE, 2018–2030 (USD MILLION)

TABLE 85 LATIN AMERICA: RETINA HEALTH MARKET, BY DISEASE INDICATION, 2018–2030 (USD MILLION)

TABLE 86 MAJOR PLAYERS IN THE GLOBAL RETINA HEALTH MARKET

TABLE 87 MOST ACTIVE PLAYERS IN THE GLOBAL RETINA HEALTH MARKET

TABLE 88 PRODUCT LAUNCH/PRODUCT APPROVAL

TABLE 89 MERGER & ACQUISITIONS

TABLE 90 EXPANSION

TABLE 91 AGREEMENT/MARKETING STRATEGIES

TABLE 92 NOVARTIS AG: PRODUCTS OFFERED

TABLE 93 NOVARTIS AG: KEY DEVELOPMENTS

TABLE 94 SPARK THERAPEUTICS, INC.: PRODUCTS/SERVICES OFFERED

TABLE 95 SPARK THERAPEUTICS, INC.: KEY DEVELOPMENTS

TABLE 96 GENSIGHT BIOLOGICS: PRODUCTS OFFERED

TABLE 97 ALLERGAN PLC: PRODUCTS/SERVICES OFFERED

TABLE 98 ALLERGAN PLC: KEY DEVELOPMENTS

TABLE 99 OXFORD BIOMEDICA PLC: PRODUCTS/SERVICES OFFERED

TABLE 100 HEMERA BIOSCIENCES LLC: PRODUCTS/SERVICES OFFERED

TABLE 101 HEMERA BIOSCIENCES LLC: KEY DEVELOPMENTS

TABLE 102 SANTEN PHARMACEUTICALS INC.: PRODUCTS OFFERED

TABLE 103 SANTEN PHARMACEUTICALS INC.: KEY DEVELOPMENTS

TABLE 104 REGENXBIO INC.: PRODUCTS OFFERED

TABLE 105 REGENXBIO INC.: KEY DEVELOPMENTS

TABLE 106 MEIRAGTX LIMITED: PRODUCTS OFFERED

TABLE 107 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC): PRODUCTS OFFERED

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS

FIGURE 2 GLOBAL RETINA HEALTH MARKET

FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL RETINA HEALTH MARKET

FIGURE 5 DRIVER IMPACT ANALYSIS

FIGURE 6 RESTRAINTS IMPACT ANALYSIS

FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL RETINA HEALTH MARKETMARKET

FIGURE 8 PORTER’S FIVE FORCES ANALYSIS: GLOBAL RETINA HEALTH MARKET

FIGURE 9 GLOBAL RETINA HEALTH MARKET, BY TREATMENT, 2021 & 2030 (USD MILLION)

FIGURE 10 GLOBAL RETINA HEALTH MARKET SHARE, BY TREATMENT (%), 2021

FIGURE 11 GLOBAL RETINA HEALTH MARKET, BY DISEASE INDICATION, 2021 & 2030 (USD MILLION)

FIGURE 12 GLOBAL RETINA HEALTH MARKET SHARE, BY DISEASE INDICATION (%), 2021

FIGURE 13 GLOBAL: RETINA HEALTH MARKET, BY REGION 2021 & 2030 (USD MILLION)

FIGURE 14 GLOBAL: RETINA HEALTH MARKET SHARE, BY REGION 2021 (%)

FIGURE 15 NORTH AMERICA: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)

FIGURE 16 EUROPE: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)

FIGURE 17 ASIA-PACIFIC: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)

FIGURE 18 REST OF THE WORLD: RETINA HEALTH MARKET SHARE, BY COUNTRY 2021 (%)

FIGURE 19 BENCHMARKING OF MAJOR COMPETITORS

FIGURE 20 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL RETINA HEALTH MARKET

FIGURE 21 GLOBAL RETINA HEALTH MARKET: COMPETITIVE LANDSCAPE

FIGURE 22 SALES (USD MILLION), 2021

FIGURE 23 RESEARCH & DEVELOPMENT EXPENDITURE 2021

FIGURE 24 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 NOVARTIS AG: SWOT ANALYSIS

FIGURE 26 ALLERGAN PLC: SWOT ANALYSIS

FIGURE 27 OXFORD BIOMEDICA PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 28 HEMERA BIOSCIENCES LLC: SWOT ANALYSIS

FIGURE 29 SANTEN PHARMACEUTICALS INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 30 SANTEN PHARMACEUTICALS INC.: SWOT ANALYSIS

FIGURE 31 REGENXBIO INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 32 REGENXBIO INC.: SWOT ANALYSIS

FIGURE 33 MEIRAGTX LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 APPLIED GENETIC TECHNOLOGIES CORPORATION (AGTC): FINANCIAL OVERVIEW SNAPSHOT